Vivos Therapeutics Analyst Ratings
BenzingaAug 20 17:34
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $6.6
Ascendiant Remains a Buy on Vivos Therapeutics (VVOS)
TipRanksApr 12, 2023 15:10
Benzinga Analyst RatingsJan 17, 2023 18:41
No Data